Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 340 | 0.82 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5421
Sealed predictions
- IFIT2 in dopamine neurons, braak+0.47 (p 0.197) → +0.26 (p 0.493)receipt 5429
Swarm cases
receipt 5429: IFIT2 in dopamine neurons, braak
- power
- full sample +0.34 (p 0.164, n 18), 95% CI -0.15 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.39 (p 0.109, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.45 (p 0.060, n 18). could be the mix.
- skeptic
- leave-one-out range +0.26 to +0.48, sign flips 0; without severely affected donors +0.34 (p 0.164, n 18). fragile.
- cell type
- strongest in microglia: +0.69 (p 0.0014, n 18) vs +0.34 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IFIT2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up IFIT2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.55 p 0.051 (needs p < 3.7e-4)
Receipts
loading the receipts